cort118335
Small moleculeexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 15, 2017 (NCT03315338)
Timeline
Indications
Mechanism of action
- Glucocorticoid receptorANTAGONIST
NR3C1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07240116 | Phase 1 | Sep 11, 2025 | Corcept Therapeutics |
| NCT04466215 | Phase 2 | Jan 16, 2021 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), Scripps |
| NCT04524403 | Phase 2 | Sep 9, 2020 | Corcept Therapeutics |
| NCT03877562 | Phase 1 | Apr 1, 2019 | Corcept Therapeutics, Quotient |
| NCT03823703 | Phase 2 | Mar 31, 2019 | Corcept Therapeutics |
| NCT03878264 | Phase 1 | Aug 6, 2018 | Corcept Therapeutics, Quotient |
| NCT03315338 | Phase 1 | Sep 15, 2017 | Corcept Therapeutics, Quotient |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Corcept Therapeutics | For profit | 6 | 6 | 2 | 2017 |
| Quotient | For profit | 3 | 0 | 1 | 2017 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 0 | 1 | 2021 |
| Scripps | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1